Various anti-IFN mAbs have been used in clinical practice (e.g., sifalimumab, an anti–IFN-α IgG1 mAb, or anifrolumab, an anti-IFNAR1 mAb, used for the treatment of SLE, in particular), and have occasionally been linked to an increase in the incidence of shingles or respiratory tract infections (Furie et al., 2017; Khamashta et al., 2016; Petri et al., 2013; Tummala et al., 2021; Table 1). Here, IFNA1 is linked to systemic lupus erythematosus.